You are here

Article Text

Article menu
Download PDFPDF
Letter
Successful treatment of squamous cell carcinoma of the lower eyelid with intralesional cidofovir
  1. D Calista1,
  2. L Riccioni2,
  3. L Coccia3
  1. 1Department of Dermatology, “M Bufalini” Hospital, Cesena, Italy
  2. 2Pathology Unit, “M Bufalini” Hospital
  3. 3Private practice, ophthalmologist, Ascoli Piceno, Italy
  1. Correspondence to: Donato Calista, MD, Department of Dermatology, “M Bufalini” Hospital, 47023 Cesena, Italy; calista{at}iol.it

https://doi.org/10.1136/bjo.86.8.932

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Cidofovir (HPMPC), an acyclic nucleoside phosphonate analogue, is a promising drug that acts against a wide number of DNA viruses.1 In 1997, the US Federal Food and Drug Administration approved cidofovir (for intravenous use only) for the treatment of cytomegalovirus retinitis in patients with AIDS.1 Over the last few years, cidofovir in a 1–3% gel or cream vehicle has been found to be effective against unmanageable viral cutaneous lesions induced by herpes, pox, and papilloma families.2 Recent studies have explored intralesional administration of cidofovir for the treatment of HPV related tumours, such as cervical epithelial neoplasia, oesophageal carcinomas, and HSV-8 induced Kaposi’s sarcoma.3–6 We report a squamous cell carcinoma (SCC) of the eyelid which was successfully …

    View Full Text